Additionally, our results indicated that high expression of FASN has a poor prognosis for anti-PD-1 treatment in GBM (Figure 6C), so the selection of immunotherapeutic approaches targeting CD276 in GBM may offer new prospects. Here, CD276 is linked to glioblastoma.